{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:43:58Z","timestamp":1791431038363,"version":"4.3.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Astellas Gene Therapies"},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR044345"],"award-info":[{"award-number":["R01AR044345"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["MDA602235"],"award-info":[{"award-number":["MDA602235"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002104","name":"Joshua Frase Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>X-linked myotubular myopathy (XLMTM) is a rare, life-threatening congenital myopathy with multisystem involvement, often requiring invasive ventilator support, gastrostomy tube feeding, and wheelchair use. Understanding healthcare resource utilization in patients with XLMTM is important for development of targeted therapies but data are limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed individual medical codes as governed by Healthcare Common Procedure Coding System, Current Procedural Terminology, and International Classification of Diseases, 10th Revision (ICD-10) for a defined cohort of XLMTM patients within a US medical claims database. Using third-party tokenization software, we defined a cohort of XLMTM patient tokens from a de-identified dataset in a research registry of diagnostically confirmed XLMTM patients and de-identified data from a genetic testing company. After approval of an ICD-10 diagnosis code for XLMTM (G71.220) in October 2020, we identified additional patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 192 males with a diagnosis of XLMTM were included: 80 patient tokens and 112 patients with the new ICD-10 code. From 2016 to 2020, the annual number of patients with claims increased from 120 to 154 and the average number of claims per patient per year increased from 93 to 134. Of 146 patients coded with hospitalization claims, 80 patients (55%) were first hospitalized between 0 and 4\u00a0years of age. Across all patients, 31% were hospitalized 1\u20132 times, 32% 3\u20139 times, and 14%\u2009\u2265\u200910 times. Patients received care from multiple specialty practices: pulmonology (53%), pediatrics (47%), neurology (34%), and critical care medicine (31%). The most common conditions and procedures related to XLMTM were respiratory events (82%), ventilation management (82%), feeding difficulties (81%), feeding support (72%), gastrostomy (69%), and tracheostomy (64%). Nearly all patients with respiratory events had chronic respiratory claims (96%). The most frequent diagnostic codes were those investigating hepatobiliary abnormalities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This innovative medical claims analysis shows substantial healthcare resource use in XLMTM patients that increased over the last 5\u00a0years. Most patients required respiratory and feeding support and experienced multiple hospitalizations throughout childhood and beyond for those that survived. This pattern delineation will inform outcome assessments with the emergence of novel therapies and supportive care measures.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02733-2","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T05:03:33Z","timestamp":1686027813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world analysis of healthcare resource utilization by patients with X-linked myotubular myopathy (XLMTM) in the United States"],"prefix":"10.1186","volume":"18","author":[{"given":"Robert J.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tmirah","family":"Haselkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casie A.","family":"Genetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weston","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8818-0568","authenticated-orcid":false,"given":"Alan H.","family":"Beggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"issue":"5","key":"2733_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/(SICI)1098-1004(200005)15:5<393::AID-HUMU1>3.0.CO;2-R","volume":"15","author":"J Laporte","year":"2000","unstructured":"Laporte J, Biancalana V, Tanner SM, et al. MTM1 mutations in X-linked myotubular myopathy. Hum Mutat. 2000;15(5):393\u2013409.","journal-title":"Hum Mutat"},{"issue":"9","key":"2733_CR2","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.nmd.2018.06.012","volume":"28","author":"I Vandersmissen","year":"2018","unstructured":"Vandersmissen I, Biancalana V, Servais L, et al. An integrated modelling methodology for estimating the prevalence of centronuclear myopathy. Neuromuscul Disord. 2018;28(9):766\u201377.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"2733_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/jnen\/nlv020","volume":"75","author":"MW Lawlor","year":"2016","unstructured":"Lawlor MW, Beggs AH, Buj-Bello A, et al. Skeletal muscle pathology in X-linked myotubular myopathy: review with cross-species comparisons. J Neuropathol Exp Neurol. 2016;75(2):102\u201310.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2733_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jbior.2016.09.001","volume":"63","author":"MA Raess","year":"2017","unstructured":"Raess MA, Friant S, Cowling BS, et al. WANTED\u2014dead or alive: Myotubularins, a large disease-associated protein family. Adv Biol Regul. 2017;63:49\u201358.","journal-title":"Adv Biol Regul"},{"issue":"4","key":"2733_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/mus.26018","volume":"57","author":"AH Beggs","year":"2018","unstructured":"Beggs AH, Byrne BJ, De Chastonay S, et al. A multicenter, retrospective medical record review of X-linked myotubular myopathy: The RECENSUS study. Muscle Nerve. 2018;57(4):550\u201360.","journal-title":"Muscle Nerve"},{"issue":"4","key":"2733_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/archdischild-2019-317910","volume":"105","author":"RJ Graham","year":"2020","unstructured":"Graham RJ, Muntoni F, Hughes I, et al. Mortality and respiratory support in X-linked myotubular myopathy: a RECENSUS retrospective analysis. Arch Dis Child. 2020;105(4):332\u20138.","journal-title":"Arch Dis Child"},{"issue":"10","key":"2733_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0960-8966(02)00153-0","volume":"12","author":"M McEntagart","year":"2002","unstructured":"McEntagart M, Parsons G, Buj-Bello A, et al. Genotype-phenotype correlations in X-linked myotubular myopathy. Neuromuscul Disord. 2002;12(10):939\u201346.","journal-title":"Neuromuscul Disord"},{"issue":"13","key":"2733_CR8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1212\/WNL.0000000000004415","volume":"89","author":"K Amburgey","year":"2017","unstructured":"Amburgey K, Tsuchiya E, de Chastonay S, et al. A natural history study of X-linked myotubular myopathy. Neurology. 2017;89(13):1355\u201364.","journal-title":"Neurology"},{"issue":"16","key":"2733_CR9","doi-asserted-by":"publisher","first-page":"e1852","DOI":"10.1212\/WNL.0000000000007319","volume":"92","author":"M Annoussamy","year":"2019","unstructured":"Annoussamy M, Lilien C, Gidaro T, et al. X-linked myotubular myopathy: A prospective international natural history study. Neurology. 2019;92(16):e1852\u201367.","journal-title":"Neurology"},{"issue":"2","key":"2733_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/S0022-3476(99)70417-8","volume":"134","author":"GE Herman","year":"1999","unstructured":"Herman GE, Finegold M, Zhao W, et al. Medical complications in long-term survivors with X-linked myotubular myopathy. J Pediatr. 1999;134(2):206\u201314.","journal-title":"J Pediatr"},{"issue":"8","key":"2733_CR11","first-page":"1019","volume":"27","author":"NC Sacks","year":"2021","unstructured":"Sacks NC, Healey BE, Cyr PL, et al. Costs and health resource use in patients with X-linked myotubular myopathy: insights from US commercial claims. J Manag Care Spec Pharm. 2021;27(8):1019\u201326.","journal-title":"J Manag Care Spec Pharm"},{"issue":"16","key":"2733_CR12","doi-asserted-by":"publisher","first-page":"e1535","DOI":"10.1212\/WNL.0000000000008316","volume":"93","author":"BT Cocanougher","year":"2019","unstructured":"Cocanougher BT, Flynn L, Yun P, et al. Adult MTM1-related myopathy carriers: classification based on deep phenotyping. Neurology. 2019;93(16):e1535\u201342.","journal-title":"Neurology"},{"key":"2733_CR13","unstructured":"Datavant. Overview of Datavant's de-identification and linking technology for structured data. https:\/\/datavant.com\/wp-content\/uploads\/dlm_uploads\/2018\/09\/WhitePaper_-De-Identifying-and-Linking-Structured-Data.pdf. Accessed March 14, 2022."},{"issue":"1","key":"2733_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JND-210712","volume":"9","author":"C Molera","year":"2021","unstructured":"Molera C, Sarishvili T, Nascimento A, et al. Intrahepatic cholestasis is a clinically significant feature associated with natural history of X-linked myotubular myopathy (XLMTM): a case series and biopsy report. J Neuromuscul Dis. 2021;9(1):73\u201382.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"2733_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s13023-021-02055-1","volume":"16","author":"A D'Amico","year":"2021","unstructured":"D\u2019Amico A, Longo A, Fattori F, et al. Hepatobiliary disease in XLMTM: a common comorbidity with potential impact on treatment strategies. Orphanet J Rare Dis. 2021;16(1):425.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2733_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/JND-200539","volume":"8","author":"A Gangfuss","year":"2021","unstructured":"Gangfuss A, Schmitt D, Roos A, et al. Diagnosing X-linked myotubular myopathy\u2014a German 20-year follow up experience. J Neuromuscul Dis. 2021;8(1):79\u201390.","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"2733_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.nmd.2021.04.009","volume":"31","author":"JM Neese","year":"2021","unstructured":"Neese JM, Yum S, Matesanz S, et al. Intracranial hemorrhage secondary to vitamin K deficiency in X-linked myotubular myopathy. Neuromuscul Disord. 2021;31(7):651\u20135.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2733_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s13104-022-06243-5","volume":"15","author":"D Kiernan","year":"2022","unstructured":"Kiernan D, Carton T, Toh S, et al. Establishing a framework for privacy-preserving record linkage among electronic health record and administrative claims databases within PCORnet((R)), the National Patient-Centered Clinical Research Network. BMC Res Notes. 2022;15(1):337.","journal-title":"BMC Res Notes"},{"issue":"4","key":"2733_CR19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1055\/a-1910-4154","volume":"13","author":"EV Bernstam","year":"2022","unstructured":"Bernstam EV, Applegate RJ, Yu A, et al. Real-world matching performance of deidentified record-linking tokens. Appl Clin Inform. 2022;13(4):865\u201373.","journal-title":"Appl Clin Inform"},{"issue":"1","key":"2733_CR20","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1038\/s41467-018-07057-5","volume":"9","author":"N Maani","year":"2018","unstructured":"Maani N, Sabha N, Rezai K, et al. Tamoxifen therapy in a murine model of myotubular myopathy. Nat Commun. 2018;9(1):4849.","journal-title":"Nat Commun"},{"issue":"9","key":"2733_CR21","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1172\/JCI86841","volume":"126","author":"N Sabha","year":"2016","unstructured":"Sabha N, Volpatti JR, Gonorazky H, et al. PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models. J Clin Invest. 2016;126(9):3613\u201325.","journal-title":"J Clin Invest"},{"issue":"3","key":"2733_CR22","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1172\/JCI71206","volume":"124","author":"BS Cowling","year":"2014","unstructured":"Cowling BS, Chevremont T, Prokic I, et al. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. J Clin Invest. 2014;124(3):1350\u201363.","journal-title":"J Clin Invest"},{"issue":"14","key":"2733_CR23","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1093\/hmg\/ddn112","volume":"17","author":"A Buj-Bello","year":"2008","unstructured":"Buj-Bello A, Fougerousse F, Schwab Y, et al. AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis. Hum Mol Genet. 2008;17(14):2132\u201343.","journal-title":"Hum Mol Genet"},{"issue":"220","key":"2733_CR24","doi-asserted-by":"publisher","first-page":"220ra10","DOI":"10.1126\/scitranslmed.3007523","volume":"6","author":"MK Childers","year":"2014","unstructured":"Childers MK, Joubert R, Poulard K, et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med. 2014;6(220):220ra10.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2733_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/mus.25658","volume":"56","author":"M Elverman","year":"2017","unstructured":"Elverman M, Goddard MA, Mack D, et al. Long-term effects of systemic gene therapy in a canine model of myotubular myopathy. Muscle Nerve. 2017;56(5):943\u201353.","journal-title":"Muscle Nerve"},{"issue":"4","key":"2733_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ymthe.2017.02.004","volume":"25","author":"DL Mack","year":"2017","unstructured":"Mack DL, Poulard K, Goddard MA, et al. Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs. Mol Ther. 2017;25(4):839\u201354.","journal-title":"Mol Ther"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02733-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T05:05:29Z","timestamp":1686027929000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02733-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2733"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02733-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"18 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data collection followed HIPAA and insurance industry standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript contains no individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TH and WM are employees and shareholders of Astellas Gene Therapies (formerly, Audentes Therapeutics). AHB has consulted and received compensation or honoraria from Astellas Gene Therapies, Biogen, F. Hoffman-La Roche AG, Kate Therapeutics, GLG Inc, and\u00a0Guidepoint Global, he holds equity in KineaBio and Kate Therapeutics and is an inventor on a US patent describing a method for gene therapy of XLMTM. DF is an employee of IPM.ai, which received funding from Astellas Gene Therapies for this study analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}